Table 6.

Number (%) of subjects with most frequently reported AEs

	OC study		Warfarin study			Rosuvastatin study			Simvastatin study
Preferred term	OC alone n = 33	OC + fostamatinib n = 30	Warfarin alone n = 15	Fostamatinib alone n = 14	Warfarin + fostamatinib n = 14	Rosuvastatin alone n = 21	Fostamatinib alone n = 21	Rosuvastatin + fostamatinib n = 21	Simvastatin alone n = 21	Fostamatinib alone n = 20	Simvastatin + fostamatinib n = 19
Any AE	16 (48.5)	8 (26.7)	3 (20.0)	1 (7.0)	2 (14.0)	3 (14.3)	2 (9.5)	3 (14.3)	3 (14.3)	6 (30.0)	2 (10.5)
Abdominal pain	1 (3.0)	1 (3.3)				0	0	0	0	1 (5.0)	0
Constipation	1 (3.0)	0				1 (4.8)	0	0	0	1 (5.0)	0
Diarrhea						0	0	1 (4.8)	0	1 (5.0)	0
Nausea	1 (3.0)	1 (3.3)	1 (7.0)	0	0	0	0	0	0	0	0
Headache	8 (24.2)	0				1 (4.8)	0	0	0	0	0
Pre-syncope	2 (6.1)	1 (3.3)				0	0	0	0	0	0
Hypoesthesia			0	1 (7.0)	0	0	0	0	0	0	0
Lethargy			1 (7.0)	0	0	0	0	0	0	0	0
Fatigue	3 (9.1)	0				0	0	0	0	0	0
Vaginal hemorrhage	2 (6.1)	0				0	0	0	0	0	0
Pollakiuria			1 (7.0)	0	0	0	0	0	0	0	0
Vessel puncture site reaction						0	0	2 (9.5)	0	0	0
Upper respiratory tract infection	0	1 (3.3)				0	0	1 (4.8)	0	1 (5.0)	0
Vulvovaginal candidiasis	2 (6.1)	0				0	0	0	0	0	0
Cough						0	0	0	1 (4.8)	1 (5.0)	0
Nasal congestion						0	0	0	1 (4.8)	0	1 (5.3)
Oropharyngeal pain	2 (6.1)	0				0	0	0	0	1 (5.0)	0
Rash	0	1 (3.3)	0	0	2 (14.0)	0	0	0	0	0	0
Contact dermatitis						0	0	0	0	1 (5.0)	1 (5.3)

In the warfarin study, the fostamatinib alone phase relates to days 8–12 where fostamatinib was dosed alone before warfarin was co-administered on day 13

AE adverse event, OC oral contraceptive